Pluristem Therapeutics (NASDAQ:PSTI) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.
Earnings and Valuation
This table compares Pluristem Therapeutics and Genfit’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Pluristem Therapeutics||$20,000.00||6,920.62||-$29.15 million||N/A||N/A|
|Genfit||$45.88 million||3.92||-$72.96 million||($1.97)||-2.35|
This table compares Pluristem Therapeutics and Genfit’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current recommendations and price targets for Pluristem Therapeutics and Genfit, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Pluristem Therapeutics presently has a consensus target price of $9.75, indicating a potential upside of 122.10%. Genfit has a consensus target price of $10.60, indicating a potential upside of 128.94%. Given Genfit’s higher probable upside, analysts clearly believe Genfit is more favorable than Pluristem Therapeutics.
Volatility & Risk
Pluristem Therapeutics has a beta of 2.53, indicating that its stock price is 153% more volatile than the S&P 500. Comparatively, Genfit has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500.
Institutional & Insider Ownership
12.0% of Pluristem Therapeutics shares are owned by institutional investors. Comparatively, 0.4% of Genfit shares are owned by institutional investors. 4.9% of Pluristem Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Pluristem Therapeutics beats Genfit on 6 of the 11 factors compared between the two stocks.
About Pluristem Therapeutics
Pluristem Therapeutics, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic tests for the identification of patients with NASH; NIS4 for identifying patients with NASH and fibrosis; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.